Turnstone Biologics Corp.
TSBX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.01 | 0.01 |
| FCF Yield | -51.81% | -74.75% | -143.62% | -136.23% |
| EV / EBITDA | 1.43 | 1.01 | 1.47 | 0.54 |
| Quality | ||||
| ROIC | -35.29% | -43.54% | -34.45% | -37.87% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.78 | 0.60 | 1.28 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -63.04% | -70.90% | -69.80% | -100.00% |
| Free Cash Flow Growth | 39.30% | 56.91% | 5.87% | -8.45% |
| Safety | ||||
| Net Debt / EBITDA | 2.93 | 1.84 | 2.51 | 1.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -506.81 | -77.60 | -100.80 |